膜性肾病 中国就医指南

Membranous Nephropathy (MN) is a chronic autoimmune kidney disorder characterized by the thickening of the glomerular basement membrane due to immune complex deposition—primarily IgG and complement component C3—along the subepithelial surface of podocytes. This leads to podocyte injury, disruption of the filtration barrier, and consequent heavy proteinuria, often presenting as nephrotic syndrome (edema, hypoalbuminemia, hyperlipidemia, and thrombotic risk). MN is classified as primary (idiopathic, ~75% of cases) when no underlying cause is identified, or secondary when associated with conditions such as systemic lupus erythematosus, hepatitis B or C infection, solid tumors (e.g., lung, gastric, or colorectal cancers), autoimmune thyroid disease, or exposure to certain medications (e.g., NSAIDs, penicillamine, or gold salts). Pathogenesis centers on autoantibodies targeting podocyte antigens—most commonly phospholipase A2 receptor (PLA2R) in adults (found in ~70–80% of primary MN), and less frequently thrombospondin type-1 domain-containing 7A (THSD7A) or neural epidermal growth factor-like 1 (NELL-1). These antibodies trigger complement activation (via the lectin or alternative pathways), resulting in subepithelial immune deposits, podocyte foot process effacement, and progressive protein leakage. Epidemiologically, MN is the most common cause of adult-onset nephrotic syndrome in non-diabetic populations, with an incidence of approximately 8–10 cases per million per year globally. It peaks between ages 40–60, shows a male predominance (M:F ≈ 2:1), and exhibits higher prevalence in North America and Europe compared to Asia—though incidence in China is rising, likely reflecting improved diagnostic awareness and PLA2R testing availability. Key risk factors include older age, male sex, PLA2R antibody titer level and persistence, elevated serum creatinine at diagnosis, and non-immunologic comorbidities such as hypertension and obesity. Importantly, up to one-third of untreated patients experience spontaneous remission within 5 years; however, another third progress to end-stage kidney disease over 10–15 years without intervention. Quality of life is significantly impaired: persistent edema and fatigue limit physical activity and work capacity; recurrent infections and hypercoagulability increase hospitalization risk; dietary restrictions (low-salt, low-protein) affect psychosocial well-being; and long-term immunosuppression carries risks of diabetes, osteoporosis, cataracts, and malignancy. Patients also face anxiety related to unpredictable disease course, fertility concerns, and financial burden from repeated lab monitoring (PLA2R titers, urine protein-to-creatinine ratio), renal biopsies, and prolonged therapy. Early diagnosis via serologic testing (anti-PLA2R/THSD7A) and confirmatory kidney biopsy remains critical for risk stratification and timely, individualized treatment.

# 膜性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：初发、低风险（PLA2R抗体阴性/低滴度、尿蛋白<4g/d、eGFR正常）患者

• •基础治疗：限盐（<6g/d）、ACEI/ARB（如缬沙坦）控制血压及蛋白尿

• •免疫抑制治疗（中高风险）：

- 药物费：1800–4500元/月；血药浓度监测（每月）：200–400元/次 - *B细胞靶向方案（利妥昔单抗）*：375mg/m²×4次（间隔1周） - 药费+输注费：12,000–28,000元/疗程；PLA2R抗体动态监测（每次）：320元

二、介入/核心治疗方案

无根治性手术：膜性肾病属免疫介导性肾小球病，不适用手术切除或透析替代作为一线治疗；仅终末期（eGFR<15ml/min）转入肾脏替代治疗。

• •血液净化支持（并发症期）：

- 术前评估（心超、血管通路造影等）：2200–4800元

三、特殊复杂情况处理

• •复发/耐药者：环磷酰胺冲击或新型CD20单抗（奥妥珠单抗）——18,000–35,000元/疗程
• •血栓高风险（肾病综合征+D-二聚体↑）：低分子肝素+华法林抗凝，年费用约2600–5200元
• •进展至CKD 4–5期：综合管理+转诊至肾移植评估（术前全套检查：15,000–22,000元）

四、方案快速选择指南

• •预算有限/初诊低风险：ACEI/ARB+生活方式干预（年总费用≤2000元）
• •中高风险/需免疫干预：利妥昔单抗方案（首年总费用约1.8–3.2万元，疗效优、副作用少）
• •反复复发/多线失败：转诊至国家级肾病中心行个体化B细胞靶向治疗